Cancer Advances Inc. is a biotechnology company focused on impacting human health and the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.
Cancer Advances is a wholly owned subsidiary of Cato BioVentures. The company's lead compound, Polyclonal Antibody Stimulator (PAS), is an immunomodulator used to treat gastrointestinal cancer. Please visit our Product page for more information on what is in development.
Avicin Therapeutics Ltd. is a clinical stage biotechnology company which is developing a novel and innovative plant-based pharmaceutical for the treatment of cancer.
Avicin Therapeutics Ltd. was formed in 2013 and is a wholly owned subsidiary of Cato BioVentures.
Hemodynamic Therapeutics Inc. (HTI) is developing its novel small molecule combination therapy (HTI-101) for obesity-related hypertension, one of the world's fastest growing cardiovascular disease markets.HTI-101 is in Phase 2 clinical development.
Contact us to learn about more companies
we have invested in and grown:
Call: 919-361-2286 or Send Us an Email